<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04088955</url>
  </required_header>
  <id_info>
    <org_study_id>PRO 1676</org_study_id>
    <nct_id>NCT04088955</nct_id>
  </id_info>
  <brief_title>A Digimed Oncology PharmacoTherapy Registry</brief_title>
  <acronym>ADOPTR</acronym>
  <official_title>A Pragmatic, Non-Interventional Study of DigiMeds™ in Combination With Standard of Care for Treatment of Patients With Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Proteus Digital Health, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Proteus Digital Health, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      DigiMeds™ are medications with FDA-approved ingestible sensors (IS), a wearable sensor patch&#xD;
      (patch), and a mobile app, which records time-stamped medication type and dose alongside&#xD;
      biometric activity.&#xD;
&#xD;
      The aim of this registry is to collect and analyze data on the use of DigiMeds™ and a digital&#xD;
      feedback system on medication adherence, patient-provider communication, and data-driven&#xD;
      optimization of therapy for cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be prescribed the DMP and DigiMeds™ (capecitabine or supportive medications) by&#xD;
      their healthcare provider. The pharmacy will co-encapsulate the prescribed medication with a&#xD;
      sensor.&#xD;
&#xD;
      The actual doses of DigiMeds™ will be based on standard of care as prescribed by treating&#xD;
      physician. Patients will be instructed in the use of the DigiMeds™ and the DMP based on&#xD;
      standard of care plus use of the DMP system.&#xD;
&#xD;
      Every effort should be made to take the DigiMeds™ as prescribed.&#xD;
&#xD;
      Patients in this study will be given the option to use their personal smartphone or will be&#xD;
      provided a provisioned iPad to use for the duration of the study. Each patient will receive a&#xD;
      Starter Kit comprised of two wearable sensor pods, adhesive strips, and instructions.&#xD;
      Additionally, some kits may contain the provisional iPad Mini and charger for those without&#xD;
      an approved smart device. Should a device malfunction occur, such as a broken pod, the&#xD;
      patient can replace it with their spare pod. Broken pods should be returned to Proteus as&#xD;
      soon as possible and all pods must be returned to the clinic upon completion of the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 6, 2019</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the duration of actual vs. intended treatment for cancer patients on capecitabine who are prescribed capecitabine with sensor.</measure>
    <time_frame>Up to 6 months from the date of inclusion into study</time_frame>
    <description>Determine how long patients can stay on treatment when using DigiMeds</description>
  </primary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Colon Cancer</condition>
  <condition>Breast Cancer</condition>
  <condition>Rectal Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>DigiMeds</intervention_name>
    <description>Digitized Capecitabine</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals diagnosed with colon, rectal, or breast cancer and diagnosed therapy with&#xD;
        capecitabine.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥ 18&#xD;
&#xD;
          -  Prescribed treatment with DigiMeds™&#xD;
&#xD;
          -  Have an Android or iOS-enabled device (e.g., iPhone, iPad, Samsung) or be willing to&#xD;
             use a Proteus issued iOS device&#xD;
&#xD;
          -  Signed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Receiving palliative or hospice care services (i.e., proxy for &lt;12 months life&#xD;
             expectancy)&#xD;
&#xD;
          -  Not proficient in the English language&#xD;
&#xD;
          -  Have impaired cognitive ability&#xD;
&#xD;
          -  For women: current pregnancy&#xD;
&#xD;
          -  Have skin sensitivity to adhesives or active/chronic dermatitis&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sinette Heys</last_name>
    <role>Study Director</role>
    <affiliation>Proteus Digital Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Carolina Blood and Cancer Care</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 13, 2019</study_first_posted>
  <last_update_submitted>March 9, 2020</last_update_submitted>
  <last_update_submitted_qc>March 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DigiMeds</keyword>
  <keyword>Capecitabine</keyword>
  <keyword>Standard of Care</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

